TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
Go back to TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities| Dreyfus/Laurel Funds Trust Dreyfus Core Value Fund Class I (NASDAQ: TCRX) | Delayed: 0.74 -0.02 (2.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.76 | 52 Week High | $26.80 | |||
| Open | $0.78 | 52 Week Low | $23.00 | |||
| Day High | $0.78 | P/E | N/A | |||
| Day Low | $0.73 | EPS | $0.00 | |||
| Volume | 253,903 | |||||
